Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline to proceed with Rotarix treatment

GlaxoSmithKline to proceed with Rotarix treatment

4th April 2008

GlaxoSmithKline (GSK) has announced that the application for approval of its Rotarix treatment has been successful.

The company states that it has received the backing of the US Food and Drug Administration for the production of the drug – which aims to prevent the development of rotavirus gastroenteritis in young children.

It has previously been recommended that infants under the age of six months should be immunised against the disease as it can severely affect this age group.

GSK hopes Rotarix will reduce the number of children affected by the symptoms of the virus each year – a number which the group’s vice president and director for vaccine development, Dr Barbara Howe, believes is significant.

“With only two doses, Rotarix allows infants to complete the vaccination series against rotavirus earlier than ever before which may prevent many ? emergency department visits and hospitalisations,” she said.

There are seven species of rotavirus – of which rotavirus A is the most prevalent and is the cause of around 90 per cent of human infections, the China Post reports.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.